Table 1 Characteristics of the 16 HCV-MC vasculitis patients at baseline and at the end of follow-up*
ParameterBaselineEnd of follow-upp Value
Age, years58 (10.5)
Female gender, n (%)13 (81.2)
MC vasculitis duration, months50.2 (57.6)
Clinical (n = 16)
    CR10 (62.5)
    PR5 (31.2)
    NR1 (6.2)
    Relapse2 (12.5)
    Arthralgia, n (%)6 (37.5)1 (6.2)0.07
    Purpura, n (%)13 (81.2)2 (12.5)0.003
    Leg ulcer, n (%)2 (12.5)0 (0)0.48
    Peripheral neuropathy, n (%)13 (81.2)8 (50.0)0.07
    Kidney involvement, n (%)7 (43.8)3 (18.8)0.13
    Serum creatinine, μmol/l105.4 (83.0)71.3 (22.4)0.78
    Glomerular filtration rate, ml/min66.6 (28.7)83.4 (24.5)0.007
    Haematuria, n (%)7 (43.7)0 (0)0.02
    Proteinuria, n (%)1.6 (2.5)0.1 (0.2)0.02
Immunological
    CR10 (62.5)
    PR5 (31.2)
    NR1 (6.2)
    Relapse2 (12.5)
    Cryoglobulin of type II, n (%)14 (87.5)
    Cryoglobulin positive, n (%)16 (100)8 (50.0)0.01
    Cryoglobulin level, g/l1.1 (0.9)0.2 (0.3)0.004
    RF activity, IU/l173.3 (55.7)42.6 (28.0)0.01
    C4 level, g/l0.06 (0.09)0.12 (0.10)0.009
    IgM level, g/l1.8 (0.7)1.2 (0.6)0.21
Virological
    CR11 (62.5)
    NR5 (68.7)
    Relapse3 (18.8)
    HCV genotype 1, n (%)10 (62.5)
    HCV RNA positive16 (100)8 (50.0)0.01
    HCV RNA, log copies/ml5.8 (0.6)4.2 (1.4)0.03
    ALT (ULN)1.8 (0.6)1.3 (0.5)0.04
    Cirrhosis4 (25)
  • HCV-MC, hepatitis C virus associated mixed cryoglobulinaemia; RF, rheumatoid factor; CR, complete response; PR, partial response; NR, non-response; ALT, alanine aminotransferase; ULN, upper limit of normal value.

  • *Except where indicated otherwise values are the mean (SD).